CAMBRIDGE, Mass.--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, announced today that the company has received €2 million in financing from funds managed by A Plus Finance.
The amount raised reinforces investors’ confidence in IntegraGen’s efforts to develop and market advances in molecular diagnostics and the company’s financial performance in the field of genomic services. Building upon an existing strong cash position, these funds will sustain the development of genetic tests in colorectal and liver cancer as well as speed up R&D and commercialization efforts in the field of autism molecular diagnostics.
Bernard Courtieu, Chief Executive Officer of IntegraGen stated “We are extremely satisfied with this capital infusion which was achieved during extremely difficult market conditions. This is a testimonial to investors’ confidence in IntegraGen’s efforts, specifically those associated with the commercialization of a genetic autism screening test this year in the USA, as well as our progress in the field of oncology biomarkers. Based on our very strong cash position, we will be able to pursue our development efforts with even greater confidence.”
Founded in 2000, IntegraGen is a biotechnology company specialized in the research and identification of genetic biomarkers for the development and marketing of products and services for molecular diagnosis. The IntegraGen mission is to offer clinicians new personalized tools for diagnosis, treatment and therapy. IntegraGen and its American affiliate IntegraGen Inc. strive for the prevention and proactive management of complex, debilitating illnesses and disorders by delivering the best response to the needs of clinicians and their patients. The Business Genomic Services division at IntegraGen also provides cutting edge services in the genotyping domain for scientific research. With research and intellectual property focused on autism and oncology, IntegraGen’s strategy is to offer a range of products and services for molecular screening and diagnosis to optimize personalized healthcare for complex illnesses and conditions.
As of December 31, 2011, IntegraGen has 26 employees. The Company had annual revenues of €4.6M from services for the fiscal year 2011. Its headquarters are located at Genopole d’Evry. The Company’s affiliate, IntegraGen Inc., is based in Cambridge, MA in the United States. IntegraGen is listed on Alternext of the NYSE Euronext in Paris (Isin: FR0010908723 – Mnémo: ALINT)
IntegraGen is listed on the Alternext market of the NYSE Euronext in Paris (Isin: FR0010908723 - Mnémo: ALINT)
More information on www.integragen.com.